This Stock Is Lifting an Entire Country's Economy -- Is It a Buy?
Some experts say Denmark's economy has performed better than that of most other European countries since the pandemic. And the country likely owes much of that to its pharmaceutical industry. One company that has been at the center of this phenomenon is Novo Nordisk (NYSE: NVO), a biotech that specializes in diabetes and obesity care.
In addition to helping push Denmark's economy forward, Novo Nordisk could deliver excellent returns to investors over the long run. Let's find out why.
One of Novo Nordisk's fastest-growing products is weight-loss medicine Wegovy. It was first approved in the U.S. in mid-2021 and has been on fire since. The clamor for Wegovy has been so high that Novo Nordisk has had trouble meeting this demand.
Source Fool.com
